Add this Page to Facebook!   Submit to Twitter   Submit to Reddit   Submit to Stumble Upon   Pin It!   Fark It!   Tell A Friend  
Printer Friendly Page Save As Favorite Save As Favorite View Article Stats
No comments

General News

It's Deja Vu All Over Again for Pfizer

By (about the author)     Permalink       (Page 1 of 2 pages)
Related Topic(s): ; ; ; ; ; ; ; , Add Tags Add to My Group(s)

View Ratings | Rate It

Headlined to H3 10/5/09

Become a Fan
  (69 fans)

opednews.com

Pfizer's $2.3 billion settlement announced last month by the US Department of Justice, for fraudulent marketing of Bextra, Geodon, Lyrica and Zyvox inducts the world's biggest drug maker into the pharma Three-Peat Hall of Fame.

It's only been five years since Pfizer agreed to pay $430 million for seizure drug Neurontin abuses and entered into a Corporate Integrity Agreement (CIA), a trust-but-verify arrangement with the Office of Inspector General of the Department of Health and Human Services, in 2004.

And it's only been seven years since Pfizer agreed to pay $49 million to settle charges it defrauded Medicaid by overcharging for cholesterol drug Lipitor and entered into another CIA in 2002.

Pfizer's fraud settlement for pain drug Bextra, withdrawn in 2004, antipsychotic Geodon, seizure drug Lyrica and antibiotic Zyvox is the largest pharmaceutical fraud settlement in the history of the Department of Justice--and the largest criminal fine ever imposed in the United States.

More than 10,000 postal employees on workers compensation were treated with Bextra, Geodon, Lyrica and Zyvox says Joseph Finn, Special Agent in Charge for the Postal Service's Office of Inspector General. Forty-three states will share in the givebacks.

But it's the same off-label and kickback tango---causing "false claims to be submitted to government health care programs," also known as our tax dollars--Pfizer has been charged with before.

For example, Florida's Medicaid program paid $935,584 for illegal Geodon pediatric prescriptions in 2005-- illegal because Geodon is not approved for children- and Texas's Medicaid program paid $557,256 for just two months of pediatric Geodon prescriptions, according to the complaint.

It is an irony that even as Pfizer settles the pediatric charges, the FDA is considering its petition to approve Geodon (ziprasidone) for children.

In June, the FDA Psychopharmacologic Drugs Advisory Committee recommended approval of Geodon for "the acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features, in children and adolescents ages 10 to 17."

And it is a further irony that the original safety data that made FDA reject Geodon as a new drug in 1997--its side effect of QT interval prolongation which can cause sudden death--are still under debate: at the June meeting, Pfizer doctors admitted to committee members that Geodon can add an extra eight heart beats a minute.

Pfizer doctors referred to the adult study 054--as they did to convince FDA to overturn Geodon's rejection in 2001--and FDA doctors insisted no prior ECG should be necessary, but doctors on the panel were less convinced.

Marsha D. Rappley, MD, Dean of the College of Human Medicine at Michigan State University observed that while the average increased heart beat with Geodon in the presented studies might be five to eight beats per minute, "there was 8 percent of the children or young people who had a pulse over 120. And if I had a 15-year-old who had a sustained pulse of 120, I would worry about that."

And Christopher B. Granger, MD, Director of Duke University Medical Center's Cardiac Care Unit and Edward L.C. Pritchett, MD, with Duke's Cardiology and Clinical Pharmacology division focused on the fact that Geodon's increased heart rate doesn't indicate blood pressure is going down as with most drugs.

"You know, the interesting thing here is that the blood pressure has actually gone up, so we have the curious situation of the heart rate and the blood pressure both going up," said Pritchett.

No one seemed reassured when Tom Tensfeldt, MD with Pfizer's pharmacokinetics group offered, "There may be a bit of a plateau in the effect, at least on average here." (Heart beats won't increase ad infinitum?)

Nor were panelists reassured when Kenneth Towbin, MD, Chief of NIMH's Clinical Child and Adolescent Psychiatry Mood and Anxiety Disorders Program asked about one of Pfizer's Geodon post marketing slides, "that revealed cardiopulmonary failure and stroke in children 3 to 17."

Next Page  1  |  2

 

Martha Rosenberg is a health reporter and commentator whose work has appeared in Consumers Digest, the Boston Globe, San Francisco Chronicle, Chicago Tribune, New Orleans Times-Picayune, Los Angeles Times, Providence Journal and Newsday. She serves (more...)
 
Add this Page to Facebook!   Submit to Twitter   Submit to Reddit   Submit to Stumble Upon   Pin It!   Fark It!   Tell A Friend
The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.

Writers Guidelines

Contact Author Contact Editor View Authors' Articles

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Grassley Investigates Lilly/WebMD link Reported by Washington Post

The Drug Store in Your Tap Water

Are You Sure You're Not Psychotic Asks Shameless Drug Company?

It's the Cymbalta Stupid

MRSA and More. Antibiotics Linked to Obesity and Allergies, Too

Another Poorly Regulated "Derivative"--the Antidepressant Pristiq

Comments

The time limit for entering new comments on this article has expired.

This limit can be removed. Our paid membership program is designed to give you many benefits, such as removing this time limit. To learn more, please click here.

Comments: Expand   Shrink   Hide  
No comments